Please assess the completion status of the following clinical trial:

Trial Title: The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. between 18 and 74 years of age,~2. have stable coronary artery disease and diabetes mellitus, already on DAPT with aspirin and clopidogrel for at least 6 months,~Exclusion Criteria:~1. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,~2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,~3. history of clinical and/or hemodynamic instability,~4. within 1 month of placement of a bare metal stent,~5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,~6. planned coronary revascularization,~7. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,~8. use of an oral anticoagulation agent or international normalized ratio \>1.5,~9. body weight \<60 kg,~10. age \>75 years,~11. hemoglobin \<10 g/dL,~12. platelet count \<100×106/μL,~13. creatinine \>2 mg/dL,~14. hepatic enzymes \>2.5 times the upper limit of normal,~15. pregnancy and/or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGLT2i (Type: EXPERIMENTAL): Empagliflozin 25 mg per oral once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).